Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Change in Accured Expenses (2016 - 2017)

Bone Biologics (BBLG) has disclosed Change in Accured Expenses for 2 consecutive years, with $613453.0 as the latest value for Q4 2017.

  • On a quarterly basis, Change in Accured Expenses rose 912.82% to $613453.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $763453.0, a 941.03% increase, with the full-year FY2025 number at $91025.0, up 1.39% from a year prior.
  • Change in Accured Expenses was $613453.0 for Q4 2017 at Bone Biologics, up from -$22181.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $613453.0 in Q4 2017 to a low of -$146082.0 in Q3 2016.